We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

J&J Keeps Cheap Risperdal Off Shelves

Law360 (May 11, 2007, 12:00 AM EDT) -- In a win for Johnson & Johnson, a U.S. appeals court has upheld a ban on the sale of a cheap version of the pharmaceutical giant’s antipsychotic drug Risperdal for the life of its key patent.

The victory was sweetened by news this week that the U.S. Food and Drug Administration had extended the patent’s life by six months after granting the company pediatric exclusivity to market its blockbuster medication.

The dark cloud in an otherwise sunny week for the drug maker was revealed in a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.